[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336841-105":59,"doc-detail-336841-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cystathionine-lyase-contributes-to-tamoxifen-resistance-and-the-compound-i194496-alleviates-this-effect-by-inhibiting-the-pparacsl1stat3-signalling-pathway-in-oestrogen-receptor-positive-breast-cancer","Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer","","Tamoxifen resistance is a major obstacle in treating oestrogen receptor-positive (ER+) breast cancer. The study investigates the role of cystathionine-γ-lyase (CSE) and its hydrogen sulfide (H2S) system in tamoxifen sensitivity and resistance, showing that CSE expression correlates with resistance and may function as a biomarker. Mechanistically, CSE/H2S modulates the PPARγ/ACSL1 axis and activates STAT3 through effects on STAT3 phosphorylation, palmitoylation and dimerization. A novel CSE inhibitor, I194496, reverses tamoxifen resistance by targeting the PPARγ/ACSL1/STAT3 signalling pathway.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cystathionine-lyase-contributes-to-tamoxifen-resistance-and-the-compound-i194496-alleviates-this-effect-by-inhibiting-the-pparacsl1stat3-signalling-pathway-in-oestrogen-receptor-positive-breast-cancer/336841/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cystathionine-lyase-contributes-to-tamoxifen-resistance-and-the-compound-i194496-alleviates-this-effect-by-inhibiting-the-pparacsl1stat3-signalling-pathway-in-oestrogen-receptor-positive-breast-cancer/336841.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does CSE relate to tamoxifen resistance in ER+ breast cancer?","Question",{"text":112,"@type":113},"CSE expression is directly associated with tamoxifen sensitivity and is involved in tamoxifen resistance in ER+ breast cancer cells, indicating potential use as a biomarker.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What signalling pathway explains the CSE-driven effect on tamoxifen resistance?",{"text":117,"@type":113},"The CSE/H2S system influences the expression of PPARγ via sulfhydrylation of PPARγ, which regulates ACSL1 transcription and ultimately affects STAT3 activation, leading to tamoxifen resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does the inhibitor I194496 play in combating tamoxifen resistance?",{"text":121,"@type":113},"I194496 reverses tamoxifen resistance in tamoxifen-resistant breast cancer by targeting the PPARγ/ACSL1/STAT3 signalling pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336841,1790165633,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCystathionine‑γ‑lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor‑positive breast cancer  \nHan Fu, Xue Han, Wenqing Guo, Xuening Zhao, Chunxue Yu, Wei Zhao, Shasha Feng, Jian Wang, Zhenshuai Zhang, Kaijian Lei*, Ming Li* & Tianxiao Wang*  \nTamoxifen (TAM) resistance is a major challenge in treating oestrogen receptor‑positive (ER+) breast cancers. It is possible that the H2S synthase cystathionine‑γ‑lyase (CSE), which has been previously shown to promote tumour growth and metastasis in other cancer cells, is involved in this resistance. Therefore, we investigated CSE’s role and potential mechanisms inTAM‑resistant breast cancer cells. First, we examined the effect ofCSE expression on TAM sensitivity and resistance in MCF7 (breast cancer) cells. The findings revealed that CSE was directly associated with TAM sensitivity and involved in TAM resistance in ER+ breast cancer cells, indicating that it may be useful as a biomarker. Next, we wanted to determine the molecular mechanism ofCSE’s role in TAM resistance. Using cell migration, co‑immunoprecipitation, western blotting, and cell viability assays, we determined that the CSE/H2S system can affect the expression of PPARγ by promoting the sulfhydrylation of PPARγ, which regulates the transcriptional activity of ACSL1. ACSL1, in turn, influences STAT3 activation by affecting the phosphorylation, palmitoylation and dimerization of STAT3, ultimately leading to the development of TAM resistance in breast cancer. Finally, we examined the effect ofCSE inhibitors on reducing drug resistance to determine whether CSE may be used as a biomarker of TAM resistance. We observed that the novel CSE inhibitor I194496 can reverse TAM resistance in TAM‑resistant breast cancer via targeting the PPARγ/ACSL1/STAT3 signalling pathway. Overall, our data indicate that CSE may serve as a biomarker of TAM resistance and that the CSE inhibitor I194496 is a promising candidate for combating TAM resistance.  \nKeywords Cystathionine-γ-lyase (CSE), TAM, Resistance, CSE inhibitor, Breast cancer  \nBreast cancer is a substantial health concern for women1,2. Breast cancer is divided into four subtypes according to the mRNA levels of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2)3,4. ER+ breast cancer is the most commonly diagnosed subtype, accounting for approximately 75% of all breast cancer cases5. For breast cancer patients with ER+ tumours, TAM is the first-line endocrine treatment. However, a considerable number of breast cancer patients develop resistance to TAM. Primary resistance affects 40–50% of patients, whereas secondary resistance affects 30–40%, posing a considerable hurdle to effective cancer treatment. As a result, understanding resistance mechanisms is critical for creating targeted medicines that reduce resistance. The development of drug resistance in tumours is strongly associated with the occurrence of metastasis. Patients who are resistant to TAM may develop tumour metastasis, which can worsen their resistance to TAM.  \nSchool of Pharmacy, Henan University, North Part of Jinming Road, Kaifeng 475004, Henan, People’s Republic of  \nChina.* email: [leikaijian@126.com](leikaijian@126.com); [liming96001@126.com](liming96001@126.com); [wtx1975@henu.edu.cn](wtx1975@henu.edu.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nHydrogen sulfide (H2S), the third gas transmitter after nitric oxide (NO) and carbon monoxide (CO), may contribute to cancer metastasis6,7. Cystathionine-γ-lyase (CSE), an endogenous H2S synthase, is highly expressed in different cancers and has been found to increase cancer cell proliferation and metastasis in various studies 8–12. These findings imply that CSE may serve as a potential therapeutic target to overcome T","cbCaia6x8J3BrxO3","https://ap.wps.com/l/cbCaia6x8J3BrxO3","pdf",14328796,14,"English","# Background and rationale\n# CSE expression and tamoxifen sensitivity\n# Molecular mechanism: CSE/H2S to PPARγ/ACSL1/STAT3\n# Therapeutic implication of CSE inhibition with I194496\n# Conclusions and significance","[{\"question\":\"How does CSE relate to tamoxifen resistance in ER+ breast cancer?\",\"answer\":\"CSE expression is directly associated with tamoxifen sensitivity and is involved in tamoxifen resistance in ER+ breast cancer cells, indicating potential use as a biomarker.\"},{\"question\":\"What signalling pathway explains the CSE-driven effect on tamoxifen resistance?\",\"answer\":\"The CSE/H2S system influences the expression of PPARγ via sulfhydrylation of PPARγ, which regulates ACSL1 transcription and ultimately affects STAT3 activation, leading to tamoxifen resistance.\"},{\"question\":\"What role does the inhibitor I194496 play in combating tamoxifen resistance?\",\"answer\":\"I194496 reverses tamoxifen resistance in tamoxifen-resistant breast cancer by targeting the PPARγ/ACSL1/STAT3 signalling pathway.\"}]","Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer | PDF",1790016841,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dbc0132d85633947df762a84cd60c91.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5078625d2a5ecc3f8e847140a707558b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a837014c534809d616a299a6908f4b0c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfa7b5e4cbad47d02401b09f05da0ff6.webp",980,1287]